Is a Normal TSH Synonymous With “Euthyroidism” in Levothyroxine Monotherapy?
Open accessThe DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
Context: Levothyroxine (LT4) monotherapy is the standard of care for hypothyroidism. Objective: To determine whether LT4 at doses that normalize the serum TSH is associated with normal markers of thyroid status. Design: Cross-sectional data from the US National Health and Nutrition Examination Survey (2001–2012) was used to evaluate 52 clinical parameters. LT4 users were compared to healthy controls and controls matched for age, sex, race, and serum TSH. Regression was used to evaluate for correlation with T4 and T3 levels. Participants: A total of 9981 participants with normal serum TSH were identified; 469 were LT4-treated. Results: Participants using LT4 had higher serum total and free T4 and lower serum total and free T3 than healthy or matched controls. This translated to approximately 15–20% lower serum T3:T4 ratios in LT4 treatment, as has been shown in other cohorts. In comparison to matched controls, LT4-treated participants had higher body mass index despite report of consuming fewer calories/day/kg; were more likely to be taking beta-blockers, statins, and antidepressants; and reported lower total metabolic equivalents. A serum TSH level below the mean in LT4-treated participants was associated with a higher serum free T4 but similar free and total T3; yet those with lower serum TSH levels exhibited higher serum high-density lipoprotein and lower serum low-density lipoprotein, triglycerides, and C-reactive protein. Age was negatively associated with serum free T3:free T4 ratio in all participants; caloric intake was positively associated in LT4-treated individuals. Conclusions: In a large population study, participants using LT4 exhibited lower serum T3:T4 ratios and differed in 12/52 objective and subjective measures.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In fact, in a cross-sectional study based on the U.S. National Health and Nutrition Examination Survey data base, serum T3 and fT3 levels were 10% lower in LT4-treated patients than in a control group matched for sex, age, ethnic background, and TSH levels (13).”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many patients with hypothyroidism also have other chronic medical conditions (13).”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“NHANES data show that patients on levothyroxine are 54% more likely to be on statins than controls matched for age, sex, and ethnic background.178”
From Hypothyroidism (2024) · cites this paper as [178]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LT4-treated patients weigh ∼10 pounds more (14)”
From Liothyronine and Desiccated Thyroid Extract in the Treatment of Hypothyroidism (2020) · cites this paper as [14]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A normal serum TSH level consequently does not necessarily indicate a euthyroid state at the tissue level [49].”
From T4+T3 Combination Therapy: An Unsolved Problem of Increasing Magnitude and Complexity (2021) · cites this paper as [49]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., et al. (2014) · Thyroid® · doi:10.1089/thy.2014.0028 · Cited by 1,928 · cited 3×
“The dogma in clinical thyroidology that LT4 monotherapy at doses that normalize serum TSH is sufficient to restore euthyroidism (1, 2) has come into question as evidence suggests a significant proportion of patients treated with LT4 continue to experience residual symptoms of hypothyroidism, including psychological (6…”
BackgroundSelf-citation(1952) · Diabetes · doi:10.2337/diab.1.2.159 · Cited by 1,447
The epidemiology of thyroid disease
Vanderpump, M. P. J. (2011) · British Medical Bulletin · doi:10.1093/bmb/ldr030 · Cited by 1,179
(1975) · Annals of Internal Medicine · doi:10.7326/0003-4819-82-2-292_1 · Cited by 641
Saravanan, P., Chau, W. ‐., Roberts, N., Vedhara, K., Greenwood, R., & Dayan, C. M. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.01654.x · Cited by 514
Conversion of Thyroxine (T4) to triiodothyronine (T3) in athyreotic human subjects
Braverman, L. E., Ingbar, S. H., & Sterling, K. (1970) · Journal of Clinical Investigation · doi:10.1172/jci106304 · Cited by 485 · cited 1×
“This strategy has been justified with the knowledge that, in humans, the iodothyronine deiodinases in peripheral tissues produce most of the circulating active form of thyroid hormone, triiodothyronine (T3), via conversion from thyroxine (T4) (4).”
BackgroundThe Thyroid: A Fundamental and Clinical Text
WERNER, S. C. (1956) · The American Journal of the Medical Sciences · doi:10.1097/00000441-195610000-00020 · Cited by 460
2012 ETA Guidelines: The Use of L-T4 + L-T3 in the Treatment of Hypothyroidism
Wiersinga, W. M., Duntas, L., Fadeyev, V., Nygaard, B., & Vanderpump, M. P. J. (2012) · European Thyroid Journal · doi:10.1159/000339444 · Cited by 437 · cited 2×
“The dogma in clinical thyroidology that LT4 monotherapy at doses that normalize serum TSH is sufficient to restore euthyroidism (1, 2) has come into question as evidence suggests a significant proportion of patients treated with LT4 continue to experience residual symptoms of hypothyroidism, including psychological (6…”
BackgroundFish, L. H., Schwartz, H. L., Cavanaugh, J., Steffes, M. W., Bantle, J. P., & Oppenheimer, J. H. (1987) · New England Journal of Medicine · doi:10.1056/nejm198703263161302 · Cited by 353 · cited 1×
“While this phenomenon has been noted in the setting of LT4 monotherapy for the last four decades, (3, 8, 22–29) there are at least two prior, smaller, studies showing that serum T3 levels can be normal in LT4-treated individuals with normal serum TSH (28, 30).”
BackgroundLevothyroxine Monotherapy Cannot Guarantee Euthyroidism in All Athyreotic Patients
Gullo, D., Latina, A., Frasca, F., Le Moli, R., Pellegriti, G., & Vigneri, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022552 · Cited by 307 · cited 1×
“One hypothesis to explain this phenomenon is that serum levels of T3 might not be fully normalized, (8) ie, T4-to-T3 conversion in these patients may be insufficient to restore levels to those achieved when thyroidal secretion of T3 is intact.”
Background
Research works printed but not linked: 1
- Medicines Use and Spending in the U.S.: A Review of 2015 and Out- look to 2020. Parsippany, NJ: IMS Institute for Healthcare Infor- matics; 2016.
Cited by
Items 101–182 of 182
Identifying the metabolic profile of Hashimoto’s thyroiditis from the METHAP clinical study
Sarandi, E., Tsoukalas, D., Rudofsky, G., Fragoulakis, V., Liapi, C. A., Paramera, E. I., Papakonstantinou, E., Krasagakis, S. K., & Tsatsakis, A. M. (2025) · Scientific Reports · doi:10.1038/s41598-025-89600-1 · Cited by 7
Design of the Optimal Trial of Combination Therapy
Cappola, A. R. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00168 · Cited by 6
“In addition, patients who are taking LT4 therapy have higher free T4 and lower T3 levels than euthyroid counterparts who are not taking LT4 (4).”
BackgroundPenna, G., Guimarães, R. O., Benseñor, I. M., Ettleson, M. D., Pires, M. C., & Bianco, A. C. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.07.023 · Cited by 4
Self-citationAzizi, F., Saadat, N., Abdi, H., Mehran, L., Masoumi, S., Takyar, M. A., & Amouzegar, A. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.004 · Cited by 5
Metabolic Consequences of Thyroidectomy and Patient-Centered Management
Wang, K., & Güleç, S. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13237465 · Cited by 7
The unique signature of tyrosine kinase inhibitor-induced hypothyroidism
Porcelli, T., Stefano, M. A. D., Luongo, C., Schlumberger, M. J., & Salvatore, D. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00193-7 · Cited by 6
A New Perspective in the Management of Graves’ Hyperthyroidism
Azizi, F. (2020) · Intern J Endocrinol Metab · doi:10.5812/ijem.102270 · Cited by 5
Mehran, L., Amouzegar, A., Foroutan, S. M., Masoumi, S., Tohidi, M., Abdi, H., Aghaei, A., Saghafinia, A. E., & Azizi, F. (2023) · BMC Endocrine Disorders · doi:10.1186/s12902-023-01434-y · Cited by 6
Levothyroxine personalized treatment: is it still a dream?
Cappelli, C., Gatta, E., & Ippolito, S. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1334292 · Cited by 7
Goede, S. L., Latham, K. R., Leow, M. K., & Jonklaas, J. (2017) · Journal of Biological Systems · doi:10.1142/s0218339017500073 · Cited by 5
Hormetic effect of triiodothyronine in metabolically healthy obese persons
Jun, J. E., Kim, T. H., Lee, S., Lee, Y., Jee, J. H., Bae, J. C., Jin, S., Hur, K. Y., Kim, J. H., Kim, S. W., et al. (2017) · Endocrine · doi:10.1007/s12020-017-1363-9 · Cited by 4
Pharmacodynamic and Therapeutic Actions of Levothyroxine
Hennessey, J. V. (2021) · 70 Years of Levothyroxine · doi:10.1007/978-3-030-63277-9_3 · Cited by 4
Levothyroxine Monotherapy: What Works Better for the Individual With Hypothyroidism?
Hennessey, J. V. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2022.12.013 · Cited by 4
(2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00179 · Cited by 4
Comparison of pathophysiology in subclinical hyperthyroidism with different etiologies
Deguchi-Horiuchi, H., Ito, M., Takahashi, S., Kousaka, K., Hisakado, M., Fukata, S., Kudo, T., Nishihara, E., Nishikawa, M., Miyauchi, A., et al. (2024) · Endocrine Journal · doi:10.1507/endocrj.ej23-0497 · Cited by 3
Ramírez, M., Bianco, A. C., & Ettleson, M. D. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae204 · Cited by 4
“Additionally, the prescription and use of statins are notably more common in this group [11, 12].”
Self-citationJeon, M. J., Lee, S. H., Lee, J. J., Han, M. K., Kim, H., Kim, W. G., Kim, T. Y., Kim, W. B., Shong, Y. K., & Ryu, J. (2019) · International Journal of Thyroidology · doi:10.11106/ijt.2019.12.1.28 · Cited by 2
The Concept of Cure in Thyroid Diseases
Azizi, F. (2020) · Intern J Endocrinol Metab · doi:10.5812/ijem.102269 · Cited by 3
“Levothyroxine replacement may cause disruption in psychological condition, lower resting energy expenditure, lower T3:T4 ratio, higher body mass index (BMI) and increased levels of serum cholesterol and LDL compared with normal controls (13-17).”
BackgroundThyroid Hormone Replacement – a Counterblast to Guidelines*
Toft, A. D. (2017) · The Journal of the Royal College of Physicians of Edinburgh · doi:10.4997/jrcpe.2017.401 · Cited by 4
Targeting the right population for T3 + T4 combined therapy: where are we now and where to next?
Porcelli, T., & Salvatore, D. (2020) · Endocrine · doi:10.1007/s12020-020-02391-5 · Cited by 3
We All Know We Need Them, We Hope They Are Coming, But When?
Bianco, A. C. (2020) · Thyroid · doi:10.1089/thy.2020.0250 · Cited by 3
“Despite normalization of serum TSH, many patients may exhibit residual symptoms that resemble tissue-specific hypothyroidism, for example, impaired cognition, sluggishness, or difficulty maintaining body weight (3).”
BackgroundSelf-citationIto, M., Deguchi-Horiuchi, H., Takahashi, S., Hisakado, M., Kohsaka, K., Nishihara, E., Fukata, S., Nishikawa, M., Miyauchi, A., & Akamizu, T. (2024) · Endocrine Journal · doi:10.1507/endocrj.ej24-0259 · Cited by 2
Tańska, K., Glinicki, P., Rebizant, B., Dudek, P., Zgliczyński, W., & Gietka‐Czernel, M. (2024) · Biomedicines · doi:10.3390/biomedicines12112628 · Cited by 5
“It has previously been observed that hypothyroid patients receiving replacement therapy with LT4 had non-physiological thyroid hormone levels, even after achieving an optimal TSH concentration, i.e., higher fT4 and lower fT3 concentrations in comparison to euthyroid subjects [47,48].”
Mazza, A. D. (2025) · Cureus · doi:10.7759/cureus.90685 · Cited by 9
“Surveys show that many clinicians, especially in Europe and North America, do offer T3 or combination therapy for patients who still have symptoms despite “normal” TSH levels and optimal T4 dosing [4,5,42,43].”
InfluentialAzizi, F. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.05.005 · Cited by 2
Persistent Hypothyroid Symptoms Despite Adequate Thyroid Hormone Replacement
McDermott, M. T. (2019) · Springer eBooks · doi:10.1007/978-3-030-22720-3_23 · Cited by 2
Liothyronine use in primary hypothyroidism — current concepts
Concepción‐Zavaleta, M. J., Ildefonso-Najarro, S. P., Paz‐Ibarra, J., Fernández-Dávila, F. V., Condori, D. C. D.-G., Rivera-Fabián, K., Herrera-Cabezas, R. G., & Urteaga, L. A. C. (2021) · Endokrynologia Polska · doi:10.5603/ep.a2021.0093 · Cited by 4
“According to the results of previous studies, patients receiving LT4 replacement therapy have a normal se - rum TSH, achieve higher total T4 and FT4 concentra - tions, and lower total T3 and FT3 serum concentrations, compared to healthy controls [22].”
Porcelli, T., Luongo, C., Cerbone, A. M., Luccio, C. D., Stefano, M. A. D., & Salvatore, D. (2025) · Endocrine Related Cancer · doi:10.1530/erc-24-0323 · Cited by 2
Azizi, F., Amouzegar, A., Abdi, H., Tohidi, M., Masoumi, S., Khalili, D., Mehrabi, Y., Zadeh–Vakili, A., Hedayati, M., Momenan, A. A., et al. (2025) · Trials · doi:10.1186/s13063-025-08940-5 · Cited by 3
“Many animal and human studies suggest that LT4 monotherapy may not be sufficient to restore euthyroidism in all tissues, as evidenced by a decreased T3 to T4 ratio, lower quality of life, and reduced resting energy expenditure [8–11].”
A Clinical Debate: What Is the Therapeutic Choice for Recurrent Graves’ Hyperthyroidism?
Abdi, H., Zakavi, S. R., & Azizi, F. (2020) · Intern J Endocrinol Metab · doi:10.5812/ijem.108876 · Cited by 2
“Better lipid profile and body mass index (53, 57);”
BackgroundLimitations of current thyroid function tests
García-Mayor, R. V. (2017) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2017.05.006 · Cited by 3
Hadi, Z. M., Alidrisi, H. A., & Mansour, A. A. (2024) · Cureus · doi:10.7759/cureus.58370 · Cited by 4
“High serum T4/T3 ratios have been found in patients with hypothyroidism treated with LT4 [14].”
BackgroundResultTsanava, I. A., Bulgakova, S. V., & Melikova, A. V. (2021) · Russian Clinical Laboratory Diagnostics · doi:10.51620/0869-2084-2021-66-5-261-265 · Cited by 1
Harsini, A. R., Mohajeri‐Tehrani, M. R., Sajjadi‐Jazi, S. M., Naeini, F., Valisoltani, N., Sadeghi, E., Mohammadi, H., & Hosseini, S. (2024) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2024.02.030 · Cited by 2
Role of T3 in Management of Hypothyroidism
Kalra, S., Mithal, A., WANGNOO, S. K., Seshadri, K., & Dharmalingnam, M. (2025) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_294_24 · Cited by 3
Eldeiry, L. S., Attanasio, R., Hegedűs, L. D., Negro, R., Papini, E., Perros, P., Gharib, H., Nagy, E. V., Žarković, M., & Garber, J. R. (2025) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2025.10.019 · Cited by 1
“33,34 37 Multivariate analysis in our study identified associations be-tween some demographic factors (male gender, medical education in the U.S. and group practice settings), and a higher likelihood to prescribe LT4/LT3 or DTE, while age > 70 and government/military practice were associated with a…”
Meneghini, V., Beltrão, F. E. D. L., Ismail, A., Hayek, S. S., Golovko, G., Khanipov, K., Ettleson, M. D., Benseñor, I. M., & Bianco, A. C. (2026) · Thyroid · doi:10.1177/10507256261460759 · Cited by 1
“30 Observational studies have further demonstrated increased statin CABG, coronary artery bypass grafting; CI, confidence interval; HR, hazard ratio; ICU, intensive care unit; MACE, major adverse cardio-vascular events; PCI, percutaneous coronary intervention; TSH, thyroid-stimulating hormone.”
Self-citationWilson’s Syndrome (Low T3 Syndrome)
Tang, C. J., & Garber, J. R. (2019) · Springer eBooks · doi:10.1007/978-3-030-22720-3_21 · Cited by 1
Pidchenko, N. S. (2020) · Український радіологічний та онкологічний журнал · doi:10.46879/ukroj.4.2020.387-402 · Cited by 1
“Також у великому популяційному дослідженні було показано, що у пацієнтів, які отримували монотерапію LT4, спостерігався вищий індекс маси тіла, вони приймали більше статинів й антидепресантів, ніж здорові пацієнти контрольної групи [23].”
InfluentialCheetham, T. D., & Boal, R. (2019) · Paediatrics and Child Health · doi:10.1016/j.paed.2019.04.006 · Cited by 1
Short-Term Dietary Modifications Can Change Serum T3:T4 Ratios
McAninch, E. A. (2023) · Clinical Thyroidology · doi:10.1089/ct.2023;35.96-98 · Cited by 2
“Many levothyroxine-treated patients report subjective and objective markers of slowed metabolism (9) and have relatively lower serum T3:T4 ratios (2).”
Self-citationAzizi, F., Moeini, A. S. H., Mehran, L., Masoumi, S., Abdi, H., Foroutan, S. M., Saghafinia, A. E., & Amouzegar, A. (2025) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2025.100395 · Cited by 4
“Clinical trials on the combination therapy of LT3 and LT4 have been frequently performed, and their pharmacodynamic and pharmacokinetic properties have been reported [3,12,29 – 31].”
Clinical thyroidology: beyond the 1970s’ TSH-T4 Paradigm
Lindner, H. H. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1529791 · Cited by 2
“They report lower physical activity levels and are more likely to be taking statins, beta-blockers, and antidepressants (202).”
McAninch, E. A. (2022) · Clinical Thyroidology · doi:10.1089/ct.2022;34.109-111 · Cited by 1
“In my clinical and research (9) experience, symptoms such as depressed mood are not always normalized even after hypothyroidism is corrected.”
Self-citationHypothyroidism Is Common Among Childhood Cancer Survivors
McAninch, E. A. (2022) · Clinical Thyroidology · doi:10.1089/ct.2022;34.196-198 · Cited by 1
“That hypothyroidism was associated with unfavorable physical health and QoL outcomes despite replacement therapy, as observed in other populations as well (6), underscores that objective differences may persist between patients with treated hypothyroidism and those with endogenous euthyroidism.”
Self-citationObjective Markers of Thyroid Hormone Homeostasis in Levothyroxine Versus Liothyronine Monotherapies
McAninch, E. A. (2022) · Clinical Thyroidology · doi:10.1089/ct.2022;34.389-391 · Cited by 1
“However, the ability of levothyroxine to “normalize” all sequelae of hypothyroidism has come into question, as a minority of patients can experience residual symptoms despite its use to normalize serum thyrotropin (TSH) (2,3).”
InfluentialSelf-citationReturning to a Patient-Centered Approach in the Management of Hypothyroidism
Schneiderhan, J. R., & Zick, S. M. (2020) · The Annals of Family Medicine · doi:10.1370/afm.2602 · Cited by 1
Idrees, T., & Bianco, A. C. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab227 · Cited by 1
Self-citationLimitations of current thyroid function tests
García-Mayor, R. V. (2017) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2017.08.013 · Cited by 1
Initial Treatment of Thyroid Cancer with Levothyroxine Results in Metabolic Changes Among Women
Angell, T. E. (2019) · Clinical Thyroidology · doi:10.1089/ct.2019;31.282-284
“Previous data have suggested that levothyroxine replacement may not normalize thyroid hormone status as compared to euthyroid controls (2).”
What is the optimal TSH level for patients with hypothyroidism on levothyroxine replacement therapy?
Larson, L. R., & Satre, T. (2018) · Evidence-Based Practice · doi:10.1097/ebp.0000000000000110
EXTENDED ABSORPTION OF LIOTHYRONINE FROM POLY-ZINC-LIOTHYRONINE (PZL) IN HUMANSPreprint
Dumitrescu, A. M., Hanlon, E. C., Arosemena, M., Duchon, O., Ettleson, M. D., Giurcanu, M. C., & Bianco, A. C. (2021) · medRxiv · doi:10.1101/2021.06.14.21258437
“First noticed around 1974 (6), subsequent studies revealed that LT4-treated patients maintain a ∼10% lower serum T3 levels (7,8).”
BackgroundSelf-citationThyroid Dysfunction and Metabolism: Diagnosis and Follow-Up
Luzi, L., Massarini, S., Terruzzi, I., Ferrulli, A., & Cusini, C. (2021) · Springer eBooks · doi:10.1007/978-3-030-80267-7_11
Hypothyroidism - A Causal Approach to Testing Assumptions against Empirical Results.
Glavin, R., Ness, R. O., & Nguyen, A. (2021) · PubMed
Pasión e identidad: el problema del conocimiento en el "De anima" de Aristóteles
Martín, J. I. A. S. (1999) · Dialnet (Universidad de la Rioja)
(2021) · The Egyptian Journal of Community Medicine · doi:10.21608/ejcm.2021.202265 · Cited by 1
(2020) · The Annals of Family Medicine · doi:10.1370/afm.2581
7 Medical Management of Thyroiditis and Hypothyroidism
(2021) · Thieme Medical Publishers eBooks · doi:10.1055/b-0041-182782
Hedayat, K. M., & Lapraz, J.-C. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816903-2.00008-2 · Cited by 2
Kim, K. E., Do, M. H., Geum, M. J., Kim, J. S., Son, E. S., & Yu, Y. M. (2022) · Journal of Korean Society of Health-System Pharmacists · doi:10.32429/jkshp.2022.39.2.002
Shames, R., & Wenzel, S. (2022) · Journal of Restorative Medicine · doi:10.14200/jrm.2022.0002 · Cited by 1
Acute Postsurgical Hypothyroidism Is Associated with Lipid Metabolite Alterations
McAninch, E. A. (2023) · Clinical Thyroidology · doi:10.1089/ct.2023;35.456-458
“…to use a low-risk group of participants with serum TSH matching (not suppression) and compare their metabolomes; this would have been a surrogate for assessment of the influence of T4:T3 ratios, which we know are elevated in LT4-treated patients even when matched for serum TSH levels (5).”
Self-citationAhmadi, S. (2024) · Clinical Thyroidology · doi:10.1089/ct.2024;36.47-50
“7 However, the benefit of restoring the physiologic FT3/FT4 ratio on a patient’s symptoms remains debatable.”
Vicuña-Herrera, I., Fernández‐Verdejo, R., & Galgani, J. E. (2024) · Revista chilena de nutrición · doi:10.4067/s0717-75182024000200103
Soni, K., & Agrawal, G. P. (2024) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2024.187582
“For hypothyroidism, levothyroxine monotherapy is the recommended course of treatment [2].”
BackgroundCombination therapy rationale in the management of hypothyroidism
Gupta, M., Saraogi, H., & Dey, A. K. (2024) · Thyroid Research and Practice · doi:10.4103/trp.trp_35_24 · Cited by 1
Correlation of Residual Symptoms With Triiodothyronine (T3) in Patients Treated for Hypothyroidism
Naushad, A. A., Chirag, L. U., Nikitha, S., Sourabh, S., Kolla, B., Selvan, C., Kalra, P., Manjunath, P., & Ganavi, Y. P. (2025) · Cureus · doi:10.7759/cureus.78095
“Globally, the prevalence of patients having residual symptoms to treatment with LT4 is estimated to be between 10% and 20% [4], with wide variation based on the symptoms.”
Brigante, G. (2025) · L Endocrinologo · doi:10.1007/s40619-025-01585-1
Special Considerations in the Treatment of Hypothyroidism
Hoermann, R., & Dietrich, J. W. (2025) · Springer eBooks · doi:10.1007/978-981-96-3682-2_12
Precision Thyroid Hormone Therapy for Hypothyroidism
Bianco, A. C., & Beltrão, F. E. D. L. (2025) · Springer eBooks · doi:10.1007/978-3-031-89650-7_24
Self-citationVudu, S., & Nizamudeen, F. (2025) · World Congress on Medical Physics and Biomedical Engineering, September 7 - 12, 2009, Munich, Germany · doi:10.1007/978-3-032-06497-4_8
Elsherbiny, H. A., Elmorsy, B. Z., Nowara, A. S., & Ghazi, H. A. (2025) · Research Square · doi:10.21203/rs.3.rs-7817249/v1
Mehran, L., Amouzegar, A., Foroutan, S. M., Masoumi, S., Tohidi, M., Abdi, H., Aghaei, A., Saghafinia, A. E., & Azizi, F. (2024) · Figshare · doi:10.6084/m9.figshare.26613242
Abdi, H., Takyar, M., Mehran, L., Masoumi, S., Amouzegar, A., & Azizi, F. (2026) · Intern J Endocrinol Metab · doi:10.5812/ijem-164940
THE ROLE OF MICRONUTRIENTS AND SUPPLEMENTS IN HYPOTHYROIDISM MANAGEMENT: A LITERATURE REVIEW
Wróbel, Z., Torbacka, K., Kaczor, J., Torbacka, M., Rozkosz, K., Wróbel, N., Jakubik, O., Podlejska, P., Sosin, A., & Bednarz, W. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4434
Ito, M., Furumura, Y., Monno, I., Deguchi-Horiuchi, H., Imamura, C., Takahashi, S., Yamaoka, H., Hisakado, M., Kohsaka, K., Nishihara, E., et al. (2026) · Thyroid Research · doi:10.1186/s13044-026-00300-y
“However, lower serum T 3 levels, which differed in both objective and subjective measures, were observed in participants with normal serum TSH levels receiving LT 4 monotherapy [11].”
Nagayama, Y., Tachibana, S., Fukuda, T., Tatsushima, D., Mori, Y., Shindo, H., Takahashi, H., Satoh, S., Nakashima, M., & Yamashita, H. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag220
Hypothyroidism Management: Beyond TSH: A Clinical Review
Mazza, A. D., & Dehn, B. (2026) · Clinical Journal for Nurse Practitioners in Women s Health · doi:10.1891/cjnpwh-2025-0063
Delivery of liothyronine by microneedle patch for the treatment of hypothyroidism
Gomaa, Y. A., Hasin, T., Griffin, M. N., Nguyen, T. C., Noel, R. K., O’Farrell, L., McAninch, E. A., Kaiser, A. M., Wood, L. B., & Prausnitz, M. R. (2026) · Drug Delivery and Translational Research · doi:10.1007/s13346-026-02214-6
Self-citationGalbiati, F., Wronski, M., Bitar, T., Bikas, A., Lamont, H., Hiranandani, S., Holman, K., Eddy, K. T., Asanza, E., Smith, S., et al. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag291
Altun, G., & Çiftel, E. (2026) · Medicina · doi:10.3390/medicina62102017
“LT4-treated patients are generally reported to have higher FT4, with FT3 lower or unchanged, than untreated individuals at a similar TSH [7–9, 20], and this was the case The absence of a TSH–outcome association in the whole cohort and in adjusted models is consistent with prior work: small changes…”
Metadata
- Authors
- Peterson, S. J., McAninch, E. A., & Bianco, A. C.
- Affiliations
- Rush University Medical Center (US)
- Corresponding author
- Bianco, Antonio C.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2016-10-04
- Volume
- 101
- Issue
- 12
- Pages
- 4964-4973
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC6287526
- OpenAlex
- W2527838986
- Cited by
- 182
- References
- 29
- Citations by year
- 2026: 9 · 2025: 19 · 2024: 21 · 2023: 17 · 2022: 17 · 2021: 24 · 2020: 29 · 2019: 22 · 2018: 11 · 2017: 12
- FWCI
- 15.08
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- levothyroxine monotherapy, hypothyroidism, thyroid-stimulating hormone, euthyroidism, free thyroxine, thyroid hormone levels, body mass index, metabolic equivalents, lipid profile, C-reactive protein, energy intake
- MeSH terms
- Adult, Aged, Cross-Sectional Studies, Female, Health Surveys, Humans, Hypothyroidism, Male, Middle Aged, Thyroid Function Tests, Thyrotropin, Thyroxine, Triiodothyronine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.